Get the Stockscreener App
3.73
0.81%
0.03
Pre-market:
3.87
0.14
+3.75%
Cervomed Inc stock is traded at $3.73, with a volume of 17,180.
It is up +0.81% in the last 24 hours and down -9.90% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$3.70
Open:
$3.71
24h Volume:
17,180
Relative Volume:
0.25
Market Cap:
$34.54M
Revenue:
$4.01M
Net Income/Loss:
$-26.97M
P/E Ratio:
-1.2556
EPS:
-2.9707
Net Cash Flow:
$-23.45M
1W Performance:
+0.54%
1M Performance:
-9.90%
6M Performance:
-49.18%
1Y Performance:
-62.51%
1-Day Range:
$3.70
$3.8399
1-Week Range:
$3.61
$3.986
52-Week Range:
$3.51
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.73 | 34.54M | 4.01M | -26.97M | -23.45M | -2.9707 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
CervoMed (CRVO) outlines 2026 virtual meeting, board slate and pay plan vote - Stock Titan
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CRVO (CervoMed) posts wider than expected Q4 2025 loss even as shares notch mild daily gains.Crowd Risk Alerts - Newser
CRVO Maintained by D. Boral Capital -- Price Target Steady at $3 - GuruFocus
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks
CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending.Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La
Neflamapimod MRI data in dementia with Lewy bodies from CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - ChartMill
What should investors watch for CervoMed (CRVO) stock (Smart Money Exits) 2026-04-20Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai
Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18Community Pattern Alerts - Cổng thông tin điện tử tỉnh Lào Cai
Operating cash flow per share of CervoMed Inc. – FWB:DP8 - TradingView — Track All Markets
CRVO Should I Buy - Intellectia AI
CRVO.O PE Ratio & Valuation, Is CRVO.O Overvalued - Intellectia AI
CRVO.O Forecast — Price Prediction for 2026. Should I Buy CRVO.O? - Intellectia AI
Buyout Rumor: Does CervoMed Inc have strong fundamentalsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
CRVO.O Technical Analysis & Stock Price Forecast - Intellectia AI
CRVO.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lewy Body Dementia Market: Accelerating Growth And Pipeline Impact By 2034 Delveinsight Cognition Therapeutics, Keiferx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Mena FN
Lewy Body Dementia Market: Accelerating Growth and Pipeline - openPR.com
CervoMed Inc. prepares Phase 3 trial after CEO engages on advancing dementia biomarkers - Traders Union
CervoMed (CRVO) Maintains "Buy" Rating with $31 Price Target | C - GuruFocus
CervoMed Inc. Provides Neflamapimod Clinical Program Update and Announces Participation at 2026 Lewy Body Dementia Association Annual Meeting - Minichart
Is CervoMed (CRVO) Stock Lagging the Market | Price at $3.79, Down 1.38%Community Breakout Alerts - Newser
CervoMed Highlights Neflamapimod Progress in Lewy Body Dementia - TipRanks
AWM-owned funds hold 405,165 shares in CervoMed (CRVO) — 4.2% stake - Stock Titan
Form 8-KCurrent report - ADVFN
CervoMed Inc. Announces Neflamapimod Clinical Trial Updates and MRI Findings at Lewy Body Dementia Association Meeting - Quiver Quantitative
CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting - ChartMill
CRVO PE Ratio & Valuation, Is CRVO Overvalued - Intellectia AI
CRVO.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
CRVO News & Events - Intellectia AI
CervoMed sets 50mg dose for phase 3 dementia trial - Investing.com
CRVO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
CRVO Technical Analysis & Stock Price Forecast - Intellectia AI
Insider Buy: How do insiders feel about CervoMed IncPrice Action & Low Risk Profit Maximizing Plans - baoquankhu1.vn
CervoMed (CRVO)’s Q4 results feature advancements in its neflamapimod program for dementia Lewy bodies (DLB) - MSN
CervoMed (CRVO)’s Q4 Results Feature Advancements in Its Neflamapimod Program for Dementia Lewy Bodies (DLB) - Insider Monkey
CEO Change: Is CervoMed Inc stock overvalued or fairly priced2026 Technicals & Risk Adjusted Swing Trade Ideas - baoquankhu1.vn
Top 5 Stocks Under $5 That Could Triple - insidermonkey.com
CervoMed Posts Investor Presentation Under Regulation FD Disclosure - TipRanks
CRVO: Phase III DLB trial launches this year, leveraging biomarker-driven selection and robust phase II data - TradingView
CervoMed (NASDAQ: CRVO) furnishes updated investor presentation via 8-K - Stock Titan
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):